Connect Biopharma Receives NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Connect Biopharma Holdings Limited (NASDAQ:CNTB) has received a deficiency notice from the Nasdaq Stock Market due to its bid price closing below the minimum $1.00 per share requirement for the last 30 consecutive business days. This puts the company's listing on the Nasdaq Global Market at risk.
September 12, 2023 | 10:02 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Connect Biopharma's stock price has been consistently below the minimum requirement, which could lead to its delisting from the Nasdaq Global Market.
The company's stock price has been below the minimum requirement for 30 consecutive business days. This could lead to its delisting from the Nasdaq Global Market, which would likely negatively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100